Table 1 Results of nontransplantation... | American Society of Hematology

Table 1

Results of nontransplantation strategies in patients with poor-risk CLL

Disease feature	N	Treatment	CRR, %	ORR, %	Median PFS, mo	Median OS, mo	Reference (year)
Fludarabine-refractory disease
	93	Alemtuzumab	2	33	5	16	Keating et al¹⁷ (2002)
	103	Alemtuzumab	4	34	8	19	Stilgenbauer et al¹⁸ (2009)
	37	FCR	6	58	NS	NS	Wierda et al¹⁹ (2005)
	30	OFAR	7	33	∼ 4 (48% at 6 mo)	∼ 12 (89% at 6 mo)	Tsimberidou et al²⁰ (2008)
	14	HDMP and rituximab	36	93	15	Not reached	Castro et al²³ (2008)
	29	Lenalidomide	7	35	12-15	23 not reached	Chanan-Khan et al²¹ (2007)
	43	Flavopiridol	0	40	12	NS	Phelps et al²² (2009)
*17p deletion and/or TP53* mutations**
	11	Alemtuzumab (frontline)	NS	64	11	NS	Hillmen et al²⁵ (2007)
	15	Alemtuzumab (salvage)	0	40	8	NS	Lozanski et al²⁶ (2004)
	29	FCR (frontline)	19	NS	∼ 12	∼ 24	Stilgenbauer et al²⁴ (2008)
	14	Lenalidomide (salvage)	0	29	12 (including 11q deletion)	NS	Ferrajoli et al²⁷ (2007)
	18	Flavopiridol (salvage)	0	39	15	NS	Phelps et al²² (2009)

Disease feature	N	Treatment	CRR, %	ORR, %	Median PFS, mo	Median OS, mo	Reference (year)
Fludarabine-refractory disease
	93	Alemtuzumab	2	33	5	16	Keating et al¹⁷ (2002)
	103	Alemtuzumab	4	34	8	19	Stilgenbauer et al¹⁸ (2009)
	37	FCR	6	58	NS	NS	Wierda et al¹⁹ (2005)
	30	OFAR	7	33	∼ 4 (48% at 6 mo)	∼ 12 (89% at 6 mo)	Tsimberidou et al²⁰ (2008)
	14	HDMP and rituximab	36	93	15	Not reached	Castro et al²³ (2008)
	29	Lenalidomide	7	35	12-15	23 not reached	Chanan-Khan et al²¹ (2007)
	43	Flavopiridol	0	40	12	NS	Phelps et al²² (2009)
*17p deletion and/or TP53* mutations**
	11	Alemtuzumab (frontline)	NS	64	11	NS	Hillmen et al²⁵ (2007)
	15	Alemtuzumab (salvage)	0	40	8	NS	Lozanski et al²⁶ (2004)
	29	FCR (frontline)	19	NS	∼ 12	∼ 24	Stilgenbauer et al²⁴ (2008)
	14	Lenalidomide (salvage)	0	29	12 (including 11q deletion)	NS	Ferrajoli et al²⁷ (2007)
	18	Flavopiridol (salvage)	0	39	15	NS	Phelps et al²² (2009)

CRR indicates complete remission rate; FCR, fludarabine, cyclophosphamide, and rituximab; OFAR, oxaliplatin, fludarabine, cytarabine, and rituximab; HDMP, high-dose methylprednisolone; and NS, not stated.

View Large

This Feature Is Available To Subscribers Only